Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference

Core Viewpoint - Anavex Life Sciences Corp. is set to present at the 24th Annual Needham Virtual Healthcare Conference, highlighting its focus on developing innovative treatments for various CNS disorders, including Alzheimer's and Parkinson's diseases [1]. Company Overview - Anavex Life Sciences Corp. (NASDAQ:AVXL) is a publicly traded biopharmaceutical company dedicated to developing novel therapeutics for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders [3]. - The company's lead drug candidate, ANAVEX®2-73 (blarcamesine), has completed multiple clinical trials for Alzheimer's disease and has shown potential in treating Parkinson's disease dementia and Rett syndrome [3]. - ANAVEX®2-73 is designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, with preclinical studies indicating its potential to halt or reverse Alzheimer's disease progression [3]. - The company is also developing ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, demonstrating disease-modifying activity against Alzheimer's disease in preclinical trials [3]. Upcoming Events - Christopher U Missling, PhD, President & CEO of Anavex, will present at the Needham Virtual Healthcare Conference on April 7, 2025, at 3:45 PM (ET) [1]. - A live audio webcast of the presentation will be available on the company's website, with an archived version accessible later that day [2].